We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » As Oral Tablet, Gilenya’s Approval Will Influence MS Prescribing Trends
As Oral Tablet, Gilenya’s Approval Will Influence MS Prescribing Trends
September 24, 2010
The FDA’s approval of Novartis’ Gilenya as the first oral treatment for relapsing remitting multiple sclerosis (MS) in the U.S. will significantly impact physician prescribing trends, according to an analysis.